Sign in
MDGL Stock Price, Chart, Stats & News
Madrigal Pharmaceuticals, Inc.
Save
11.25B
Market cap
–
Current P/E
666.67x
Forward P/E
MDGL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.14% |
Operating margin | -31.31% |
Pretax margin | -30.08% |
Net margin | -30.08% |
Effective tax rate | – |
ROA | -22.89% |
ROE | -43.76% |
D/E | 0.59x |
Interest coverage ratio | -13.45x |
MDGL valuation
P/E | – |
P/S | 12.22x |
P/B | 19.01x |
P/CF | -60.44x |
P/FCF | -61.65x |
P/OCF | -60.44x |
PEG | -36.93x |
EV multiple | -43.71x |
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom.
Similar securities
Based on sector and market capitalization
Report issue